Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05401097
Title Ivosidenib or Enasidenib Followed by Azacitidine Plus Venetoclax or Azacitidine Plus Venetoclax Followed by Ivosidenib or Enasidenib for the Treatment of IDH Mutated Acute Myeloid Leukemia in Older Patients. The I-DATA Study
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alice Mims

acute myeloid leukemia



Azacitidine + Enasidenib + Venetoclax

Azacitidine + Ivosidenib + Venetoclax


Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST